Payment overview · 2025
General Payments
$932.64
57 reported records · 15 companies
Healthcare provider profile · identity verified
Angela Rogers
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OWENSBORO, KY · NPI 1871960948
Verified facts
What the public records show
CMS Open Payments records show Angela Rogers received $932.64 in general payments during 2025 across 57 reported records.
Novo Nordisk Inc accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Ozempic, Prolia, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $239.84 | 25.7% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $228.07 | 24.4% | 13 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $159.85 | 17.1% | 11 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $57.30 | 6.1% | 3 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $31.70 | 3.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.50 | 3.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.46 | 3.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.10 | 3.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.61 | 2.6% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $19.28 | 2.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $18.78 | 2.0% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.40 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.58 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 1.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.81 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $932.64 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $211.06 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $171.71 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $159.85 | 11 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $140.00 | 7 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $57.30 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $53.27 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.80 | 3 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $31.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.10 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.66 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $12.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 230 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 31 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
230 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 62 |
| Mounjaro | Tirzepatide | 232 | 39 |
| Ozempic | Semaglutide | 230 | 44 |
| Losartan Potassium | Losartan Potassium | 225 | 50 |
| Lisinopril | Lisinopril | 212 | 57 |
| Metformin Hcl | Metformin Hcl | 209 | 47 |
| Farxiga | Dapagliflozin Propanediol | 195 | 37 |
| Synthroid | Levothyroxine Sodium | 183 | 44 |
| Furosemide | Furosemide | 180 | 46 |
| Carvedilol | Carvedilol | 169 | 40 |
| Omeprazole | Omeprazole | 169 | 34 |
| Famotidine | Famotidine | 164 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 141 | 37 |
| Jardiance | Empagliflozin | 135 | 31 |
| Sertraline Hcl | Sertraline Hcl | 122 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 27 |
| Buspirone Hcl | Buspirone Hcl | 118 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 32 |
| Potassium Chloride | Potassium Chloride | 115 | 28 |
| Ezetimibe | Ezetimibe | 113 | 36 |
| Trazodone Hcl | Trazodone Hcl | 113 | 23 |
| Montelukast Sodium | Montelukast Sodium | 109 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 26 |
| Simvastatin | Simvastatin | 97 | 27 |
| Meloxicam | Meloxicam | 90 | 23 |
| Eliquis | Apixaban | 87 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 22 |
| Allopurinol | Allopurinol | 84 | 24 |
| Metformin Hcl Er | Metformin Hcl | 82 | 25 |
| Nateglinide | Nateglinide | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 11 |
| Alendronate Sodium | Alendronate Sodium | 72 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | 15 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 67 | 12 |
| Tradjenta | Linagliptin | 66 | 13 |
| Gabapentin | Gabapentin | 62 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 12 |
| Trulicity | Dulaglutide | 58 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 14 |
| Ondansetron Odt | Ondansetron | 51 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 51 | 14 |
| Baclofen | Baclofen | 50 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 50 | 12 |
| Fluconazole | Fluconazole | 49 | 33 |
| Sucralfate | Sucralfate | 49 | 12 |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 12 |
| Vascepa | Icosapent Ethyl | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Alprazolam | Alprazolam | 47 | 14 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 47 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Novolog | Insulin Aspart | 45 | suppressed |
| Nystatin | Nystatin | 45 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 14 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 35 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 36 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 12 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Insulin Lispro | Insulin Lispro | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Prolia | Denosumab | 25 | 18 |
| Risperidone | Risperidone | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Tirosint-Sol | Levothyroxine Sodium | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $932.64 · 57 records | Novo Nordisk Inc | EVENITY, Fibroscan, GEMTESA, JARDIANCE, JOURNAVX, Kerendia, Korlym, LEQVIO, MINIMED 780G, OTEZLA, Omnipod, Ozempic, PROLIA, REPATHA, REZDIFFRA, Rybelsus, TEPEZZA, TWIIST, Wegovy, XIFAXAN, XYOSTED | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error